Alira Health secures US$58 million in capital funding

Global healthcare advisory, clinical research and technology company Alira Health has secured an additional US$58 million in capital funding.

The investment will accelerate Alira Health’s delivery of patient-centric, technology-enabled healthcare solutions.

Gabriele Brambilla, CEO and Co-Founder of Alira Health, said:

“With the Cures Act empowering patients to access their own data, Alira Health is well positioned with a significant tailwind in our favour, as we have been preparing for this major paradigm shift for years.

“We are executing on our winning strategy to become a patient-centric solutions provider, enabled by innovative technologies that will collect clinical and real-world data directly from patients, powerfully informing the development of new drugs and devices.

“Our investors are excited to share our vision and support us in our mission to positively impact the life of every patient.”

Alira Health focuses on new opportunities brought into effect in the US by federal rules preventing the blocking of electronic health information (EHI) under the 21st Century Cures Act.

This allows patients ownership and control over their own data and could be a game-changer for patients’ ability to engage in healthcare in new ways.

Benjamin Chambon, CCO and Co-Founder of Alira Heath, said:

“At Alira Health, we are ready for this revolutionary new world in which patients own their data, and are empowered not only to improve their own health, but also to help improve the health of others and solve medical problems.

“Patient data will illuminate the patient journey for life sciences companies, guiding the direction of research and development. The result will be the democratisation of life sciences research.”

Alira Health raised $35M in 2021 and $40M in 2022, with the two rounds led by Creadev.